ASEP Medical Holdings Inc (ASEP) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 3.60K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.21
• Revenue Growth: N/A
• EPS Growth: 46.25%
• Country: CA
• Employees: 6
• Sector: Healthcare
• Sector Strength: 65
• Industry: Biotechnology
• EPS (TTM): -0.62
• Shares Outstanding: 11,123,727
• 10 Day Avg. Volume: 9,212
• 30 Day Avg. Volume: 3,604
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 24.33
• Price to Cash Flow (P/CF): -19.60
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

ASEP Medical Holdings Inc exhibits substantial financial difficulties, with ongoing losses and negative cash flows weighing heavily on its overall score. The technical indicators suggest a negative market sentiment, with the stock trading below key moving averages. Valuation is poor due to negative earnings and lack of dividends, emphasizing the company's current unprofitability. Without notable improvements or strategic initiatives to enhance revenue and profitability, the stock remains a high-risk investment.

ASEP Medical Holdings Inc Business Overview & Revenue Model

Company Description

ASEP Medical Holdings Inc (ASEP) is a healthcare company focused on advancing medical technologies and solutions to improve patient outcomes. The company operates in the biotechnology and pharmaceuticals sectors, developing innovative products and services designed to address significant unmet medical needs. ASEP is committed to research and development, striving to bring cutting-edge therapies and medical devices to the market.

How the Company Makes Money

ASEP Medical Holdings Inc generates revenue through the development and commercialization of its proprietary medical technologies and solutions. The company earns money by licensing its innovations to pharmaceutical companies, healthcare providers, and medical device manufacturers. ASEP may also engage in strategic partnerships and collaborations to enhance its product offerings and expand its market reach. Additional revenue streams could include sales of its developed products, royalties from licensed technologies, and potentially government or private sector grants for research and development initiatives.

ASEP Medical Holdings Inc Financial Statement Overview

Summary

ASEP Medical Holdings Inc faces significant financial challenges with persistent losses and negative cash flows. While leverage is low, the company struggles with profitability and cash generation, which could hinder long-term sustainability. Strategic improvements in revenue generation and cost management are necessary to enhance financial health.

Income Statement

ASEP Medical Holdings Inc has shown minimal revenue growth with significant net losses over the years. The TTM (Trailing-Twelve-Months) Net Profit Margin and Gross Profit Margin are both negative, indicating a lack of profitability. Revenue growth is present but from a low base, and EBIT and EBITDA margins are also negative, suggesting ongoing operational challenges.

Balance Sheet

The balance sheet shows a modest debt-to-equity ratio, indicating low financial leverage, which is a positive aspect. However, the company has been consistently reporting negative equity in prior years, highlighting potential financial instability. The Equity Ratio is moderate but has shown a declining trend, raising concerns about asset management.

Cash Flow

Operating cash flow remains negative, reflecting challenges in generating cash from operations. Free cash flow has improved slightly in the TTM period but remains negative. The company's reliance on financing activities to support its cash flows suggests potential liquidity issues.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
243.92K	21.14K	0.00	0.00	0.00	61.17K
	Gross Profit
-232.37K	-113.74K	-155.40K	-177.18K	-26.45K	6.16K
	EBIT
-5.00M	-7.72M	-5.44M	-1.98M	-28.10K	-353.00
	EBITDA
-4.17M	-8.14M	-4.56M	-2.06M	0.00	0.00
	Net Income Common Stockholders
-4.64M	-8.23M	-5.76M	-2.30M	-28.10K	-353.00
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
64.72K	64.72K	2.13M	5.29M	8.47K	534.00
	Total Assets
25.61M	25.61M	27.08M	30.72M	10.98K	2.59K
	Total Debt
20.00K	20.00K	0.00	0.00	140.71K	110.66K
	Net Debt
-44.72K	-44.72K	-2.13M	-5.29M	132.24K	110.12K
	Total Liabilities
3.05M	3.05M	528.16K	144.20K	161.51K	125.03K
	Stockholders Equity
12.61M	12.61M	15.47M	18.26M	-150.53K	-122.43K
Cash Flow		Free Cash Flow
-1.11M	-2.72M	-3.61M	-1.31M	-22.12K	-47.96K
	Operating Cash Flow
-1.11M	-2.71M	-3.61M	-1.19M	-22.12K	-47.96K
	Investing Cash Flow
-1.25K	-4.47K	124.80K	146.08K	0.00	0.00
	Financing Cash Flow
862.26K	651.40K	330.00K	6.34M	30.06K	47.54K

ASEP Medical Holdings Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ASEP, the sentiment is Negative. The current price of 0.5 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.07, and above the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 32.84 is Neutral, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ASEP.

ASEP Medical Holdings Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$5.31B	3.33	-39.82%	2.92%	17.95%	1.84%
ASEP	31 Underperform		―	-39.43%	―	―	46.25%